Covishield Produced More Antibodies Than Covaxin In Early Study: Report

Seropositivity rates to anti-spike antibody were significantly higher in Covishield recipients compared to Covaxin after the first dose, the study claimed.

Covishield vaccine produced more antibodies than Covaxin, according to a preliminary study by Coronavirus Vaccine-induced Antibody Titre (COVAT) involving healthcare workers (HCW) who have received both doses of either of the two vaccines. Seropositivity rates to anti-spike antibody were significantly higher in Covishield recipients compared to Covaxin after the first dose, the study claimed. The study is a preprint and has not been peer-reviewed, so should not be used to guide clinical practice. It said that both vaccines-- Covishield and Covaxin-- elicited a good response after two doses, but seropositivity rate and median anti-spike antibody were significantly higher in Covishield.